Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $6,933 | 330 | 82.4% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $1,260 | 1 | 15.0% |
| Education | $219.89 | 3 | 2.6% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Incyte Corporation | $1,815 | 12 | $0 (2024) |
| ABBVIE INC. | $1,411 | 85 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $847.97 | 34 | $0 (2024) |
| LEO Pharma Inc. | $754.88 | 33 | $0 (2024) |
| Dermavant Sciences, Inc. | $556.62 | 27 | $0 (2024) |
| Janssen Biotech, Inc. | $405.40 | 24 | $0 (2024) |
| GENZYME CORPORATION | $378.45 | 12 | $0 (2024) |
| Regeneron Healthcare Solutions, Inc. | $367.74 | 14 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $345.22 | 21 | $0 (2024) |
| PFIZER INC. | $303.80 | 20 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $3,958 | 95 | Incyte Corporation ($1,756) |
| 2023 | $1,513 | 74 | E.R. Squibb & Sons, L.L.C. ($279.31) |
| 2022 | $1,728 | 96 | ABBVIE INC. ($457.94) |
| 2021 | $1,214 | 69 | AbbVie Inc. ($380.96) |
All Payment Transactions
334 individual payment records from CMS Open Payments — Page 1 of 14
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/11/2024 | E.R. Squibb & Sons, L.L.C. | Sotyktu (Drug) | Food and Beverage | Cash or cash equivalent | $21.24 | General |
| Category: Immunology | ||||||
| 12/05/2024 | Regeneron Healthcare Solutions, Inc. | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $98.50 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 12/05/2024 | GENZYME CORPORATION | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $40.00 | General |
| Category: Immunology | ||||||
| 12/05/2024 | SUN PHARMACEUTICAL INDUSTRIES INC. | Winlevi (Drug) | Food and Beverage | In-kind items and services | $26.26 | General |
| Category: Dermatology | ||||||
| 12/04/2024 | Incyte Corporation | OPZELURA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,260.00 | General |
| Category: Dermatology | ||||||
| 12/02/2024 | Dermavant Sciences, Inc. | VTAMA (Drug) | Food and Beverage | In-kind items and services | $16.86 | General |
| Category: DERMATOLOGY | ||||||
| 11/26/2024 | PFIZER INC. | CIBINQO (Drug), LITFULO | Food and Beverage | In-kind items and services | $18.30 | General |
| Category: Inflammation & Immunology | ||||||
| 11/20/2024 | E.R. Squibb & Sons, L.L.C. | Sotyktu (Drug) | Food and Beverage | Cash or cash equivalent | $18.90 | General |
| Category: Immunology | ||||||
| 11/19/2024 | Novartis Pharmaceuticals Corporation | — | Food and Beverage | In-kind items and services | $14.41 | General |
| 11/14/2024 | Incyte Corporation | OPZELURA (Drug) | Food and Beverage | Cash or cash equivalent | $18.52 | General |
| Category: Dermatology | ||||||
| 11/12/2024 | ABBVIE INC. | SKYRIZI (Biological) | Food and Beverage | In-kind items and services | $18.44 | General |
| Category: IMMUNOLOGY | ||||||
| 11/07/2024 | Incyte Corporation | OPZELURA (Drug) | Food and Beverage | Cash or cash equivalent | $137.12 | General |
| Category: Dermatology | ||||||
| 11/07/2024 | Incyte Corporation | OPZELURA (Drug) | Food and Beverage | Cash or cash equivalent | $26.73 | General |
| Category: Dermatology | ||||||
| 11/06/2024 | REVANCE THERAPEUTICS, INC. | DAXXIFY (Drug) | Food and Beverage | In-kind items and services | $80.00 | General |
| Category: AESTHETICS AND THERAPEUTICS | ||||||
| 10/29/2024 | REVANCE THERAPEUTICS, INC. | DAXXIFY (Drug) | Food and Beverage | In-kind items and services | $28.59 | General |
| Category: AESTHETICS AND THERAPEUTICS | ||||||
| 10/29/2024 | Dermavant Sciences, Inc. | VTAMA (Drug) | Food and Beverage | In-kind items and services | $15.16 | General |
| Category: DERMATOLOGY | ||||||
| 10/24/2024 | E.R. Squibb & Sons, L.L.C. | Sotyktu (Drug) | Food and Beverage | Cash or cash equivalent | $33.48 | General |
| Category: Immunology | ||||||
| 10/16/2024 | PFIZER INC. | EUCRISA (Drug), CIBINQO, LITFULO | Food and Beverage | In-kind items and services | $13.51 | General |
| Category: DERMATOLOGY | ||||||
| 10/16/2024 | Dermavant Sciences, Inc. | VTAMA (Drug) | Food and Beverage | In-kind items and services | $1.42 | General |
| Category: DERMATOLOGY | ||||||
| 09/25/2024 | E.R. Squibb & Sons, L.L.C. | Sotyktu (Drug) | Food and Beverage | Cash or cash equivalent | $15.84 | General |
| Category: Immunology | ||||||
| 09/24/2024 | Dermavant Sciences, Inc. | VTAMA (Drug) | Food and Beverage | In-kind items and services | $15.70 | General |
| Category: DERMATOLOGY | ||||||
| 09/20/2024 | ABBVIE INC. | SKYRIZI (Biological) | Food and Beverage | In-kind items and services | $26.23 | General |
| Category: IMMUNOLOGY | ||||||
| 09/17/2024 | SUN PHARMACEUTICAL INDUSTRIES INC. | Winlevi (Drug) | Food and Beverage | In-kind items and services | $21.41 | General |
| Category: Dermatology | ||||||
| 09/09/2024 | ABBVIE INC. | SKYRIZI (Biological) | Food and Beverage | In-kind items and services | $7.73 | General |
| Category: IMMUNOLOGY | ||||||
| 09/05/2024 | E.R. Squibb & Sons, L.L.C. | Sotyktu (Drug) | Food and Beverage | Cash or cash equivalent | $31.67 | General |
| Category: Immunology | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 18 | 1,416 | 2,510 | $252,546 | $107,634 |
| 2022 | 15 | 1,061 | 1,698 | $213,360 | $99,010 |
| 2021 | 19 | 1,097 | 1,765 | $265,078 | $129,743 |
| 2020 | 18 | 1,185 | 2,059 | $297,208 | $120,570 |
All Medicare Procedures & Services
70 procedure records from CMS Medicare Utilization — Page 2 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 36 | 36 | $7,807 | $3,649 | 46.7% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2022 | 56 | 56 | $8,133 | $3,279 | 40.3% |
| 17282 | Destruction of cancer skin growth of face, ears, eyelids, nose, lips, or mouth, 1.1-2.0 cm | Office | 2022 | 13 | 15 | $4,054 | $1,910 | 47.1% |
| 17003 | Destruction of precancer skin growth, 2-14 growths | Office | 2022 | 90 | 388 | $3,492 | $1,746 | 50.0% |
| 17111 | Destruction of skin growth, 15 or more growths | Office | 2022 | 12 | 18 | $3,154 | $1,630 | 51.7% |
| 11103 | Biopsy of related skin growth, each additional growth | Office | 2022 | 29 | 42 | $2,838 | $1,489 | 52.5% |
| 11603 | Removal of cancer skin growth of body, arms, or legs, 2.1-3.0 cm | Office | 2022 | 12 | 13 | $4,753 | $1,376 | 28.9% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2022 | 27 | 33 | $2,426 | $1,053 | 43.4% |
| J7308 | Aminolevulinic acid hcl for topical administration, 20%, single unit dosage form (354 mg) | Office | 2021 | 36 | 105 | $53,119 | $32,689 | 61.5% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 196 | 320 | $53,997 | $24,539 | 45.4% |
| 96574 | Application of light and light-sensitive drugs following removal of premalignant thickened skin growth, per day | Office | 2021 | 34 | 73 | $27,982 | $14,218 | 50.8% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 167 | 216 | $25,657 | $11,875 | 46.3% |
| 11102 | Tangential biopsy of single skin lesion | Office | 2021 | 130 | 168 | $23,070 | $9,750 | 42.3% |
| 17110 | Destruction of up to 14 skin growths | Office | 2021 | 102 | 115 | $17,243 | $8,086 | 46.9% |
| 17000 | Destruction of skin growth | Office | 2021 | 119 | 164 | $14,254 | $5,236 | 36.7% |
| 13121 | Repair of wound (2.6 to 7.5 centimeters) of scalp, arms, and/or legs | Office | 2021 | 12 | 15 | $8,569 | $4,150 | 48.4% |
| 11103 | Tangential biopsy of additional skin lesion | Office | 2021 | 48 | 90 | $6,255 | $3,323 | 53.1% |
| 17282 | Destruction of malignant growth (1.1 to 2.0 centimeters) of face, ears, eyelids, nose, lips, or mouth | Office | 2021 | 19 | 24 | $6,486 | $3,166 | 48.8% |
| 99203 | New patient outpatient visit, total time 30-44 minutes | Office | 2021 | 34 | 34 | $4,949 | $2,168 | 43.8% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Office | 2021 | 21 | 21 | $4,719 | $2,088 | 44.3% |
| 17262 | Destruction of malignant growth (1.1 to 2.0 centimeters) of trunk, arms, or legs | Office | 2021 | 17 | 17 | $3,987 | $1,748 | 43.8% |
| 17272 | Destruction of malignant growth (1.1 to 2.0 centimeters) of scalp, neck, hands, feet, or genitals | Office | 2021 | 15 | 16 | $3,965 | $1,715 | 43.3% |
| 17003 | Destruction of 2-14 skin growths | Office | 2021 | 81 | 318 | $2,743 | $1,375 | 50.1% |
| 10040 | Acne surgery | Office | 2021 | 16 | 16 | $2,455 | $1,159 | 47.2% |
| 99212 | Established patient outpatient visit, total time 10-19 minutes | Office | 2021 | 27 | 29 | $2,123 | $1,091 | 51.4% |
About Brian Cook, P.A.-C
Brian Cook, P.A.-C is a Physician Assistant healthcare provider based in Prosper, Texas. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 12/04/2007. The National Provider Identifier (NPI) number assigned to this provider is 1932381696.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Brian Cook, P.A.-C has received a total of $8,413 in payments from pharmaceutical and medical device companies, with $3,958 received in 2024. These payments were reported across 334 transactions from 31 companies. The most common payment nature is "Food and Beverage" ($6,933).
As a Medicare-enrolled provider, Cook has provided services to 4,759 Medicare beneficiaries, totaling 8,032 services with total Medicare billing of $456,957. Data is available for 4 years (2020–2023), covering 70 distinct procedure/service records.
Practice Information
- Specialty Physician Assistant
- Other Specialties Physician Assistant
- Location Prosper, TX
- Active Since 12/04/2007
- Last Updated 08/20/2013
- Taxonomy Code 363A00000X
- Entity Type Individual
- NPI Number 1932381696
Products in Payments
- OPZELURA (Drug) $1,815
- SKYRIZI (Biological) $870.08
- DUPIXENT (Biological) $836.14
- Sotyktu (Drug) $826.58
- ADBRY (Biological) $596.36
- VTAMA (Drug) $556.62
- TREMFYA (Drug) $366.76
- HUMIRA (Biological) $311.37
- EUCRISA (Drug) $285.50
- COSENTYX (Biological) $222.50
- RINVOQ (Biological) $203.98
- ENSTILAR (Drug) $158.52
- Winlevi (Drug) $136.11
- Klisyri (Drug) $117.60
- DAXXIFY (Drug) $108.59
- BLU-U (Medical Supply) $102.26
- COSENTYX (Drug) $92.50
- Bimzelx (Biological) $70.39
- Cimzia (Drug) $64.91
- TALTZ (Drug) $59.19
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Physician Assistant Doctors in Prosper
Elizabeth Carter, Pa, PA
Physician Assistant — Payments: $8,942
Aubry Van Noy, Mpas, Pa-C, MPAS, PA-C
Physician Assistant — Payments: $4,916
Jonathan Guinto, Pa-C, PA-C
Physician Assistant — Payments: $4,389
Lauren Deery, Pa-C, PA-C
Physician Assistant — Payments: $2,177
Mr. Nickolas Stroh, Pa-C, PA-C
Physician Assistant — Payments: $1,163
Fiona Patel, Pa, PA
Physician Assistant — Payments: $808.78